GlobeNewswire

Assemblée Générale Mixte du 27 novembre 2025 - Modalités de mise à disposition des documents préparatoires
06/11/2025
Daix (France), New York City (New York, Etats-Unis), le 6 novembre 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Statement of total voting rights and shares forming the company’s share capital as October 20, 2025
06/11/2025
Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www . i n v e n t i v a p ha r m a. c om Date Number of Shares Outstanding Total voting rights [...]
Information relative au nombre total de droits de vote et d’actions composant le capital social au 20 octobre 2025
06/11/2025
Article R. 22-10-23 du Code de commerce Place de cotation : Euronext Paris Code ISIN / Mnémo : FR0013233012 / IVA Site web : www . i n v e n t i v a p ha r m a. c om Date Nombre de titres composant le capital en [...]
ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor
06/11/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
06/11/2025
Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine release, [...]
Denali Therapeutics Announces Board and Executive Leadership Updates
06/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been [...]
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates
06/11/2025
Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-z Presenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on November 10 at AHA 2025; previously published longer-term [...]
FDA Awards Second Batch of National Priority Vouchers
06/11/2025
Silver Spring, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced six additional awardees under the Commissioner’s National Priority Voucher (CNPV) pilot program . This second [...]
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
06/11/2025
– Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that Arvind Sood has [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum